InnoCare Pharma Reports Promising Results for Zurletrectinib in Pediatric Solid Tumors

Reuters10-30

InnoCare Pharma Reports Promising Results for Zurletrectinib in Pediatric Solid Tumors

InnoCare Pharma Ltd. has announced the latest results from a phase I/II clinical trial of zurletrectinib (ICP-723), a next-generation pan-TRK inhibitor, for pediatric and adolescent patients with advanced solid tumors. The data were presented as an oral presentation at the Congress of the International Society of Paediatric Oncology (SIOP) 2025. The study demonstrated favorable safety and promising antitumor activity in patients with NTRK/ROS1-altered solid tumors, including those resistant to first-generation TRK inhibitors. The recommended phase 2 dose was established at 7.2 mg/m² for pediatric patients and 8 mg for adolescents, with pharmacokinetic profiles comparable to adults. As of July 31, 2025, the objective response rate in NTRK fusion patients was 90%, with treatment-related adverse events primarily grade 1 or 2 and no dose-limiting toxicities observed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565180-en) on October 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579066165?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 11:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579066165","market":"us","top_or_hot":-1,"title":"InnoCare Pharma Reports Promising Results for Zurletrectinib in Pediatric Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InnoCare Pharma Reports Promising Results for Zurletrectinib in Pediatric Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InnoCare Pharma Ltd. has announced the latest results from a phase I/II clinical trial of zurletrectinib (ICP-723), a next-generation pan-TRK inhibitor, for pediatric and adolescent patients with advanced solid tumors. The data were presented as an oral presentation at the Congress of the International Society of Paediatric Oncology (SIOP) 2025. The study demonstrated favorable safety and promising antitumor activity in patients with NTRK/ROS1-altered solid tumors, including those resistant to first-generation TRK inhibitors. The recommended phase 2 dose was established at 7.2 mg/m² for pediatric patients and 8 mg for adolescents, with pharmacokinetic profiles comparable to adults. As of July 31, 2025, the objective response rate in NTRK fusion patients was 90%, with treatment-related adverse events primarily grade 1 or 2 and no dose-limiting toxicities observed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565180-en) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare Pharma Reports Promising Results for Zurletrectinib in Pediatric Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare Pharma Reports Promising Results for Zurletrectinib in Pediatric Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 11:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InnoCare Pharma Reports Promising Results for Zurletrectinib in Pediatric Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InnoCare Pharma Ltd. has announced the latest results from a phase I/II clinical trial of zurletrectinib (ICP-723), a next-generation pan-TRK inhibitor, for pediatric and adolescent patients with advanced solid tumors. The data were presented as an oral presentation at the Congress of the International Society of Paediatric Oncology (SIOP) 2025. The study demonstrated favorable safety and promising antitumor activity in patients with NTRK/ROS1-altered solid tumors, including those resistant to first-generation TRK inhibitors. The recommended phase 2 dose was established at 7.2 mg/m² for pediatric patients and 8 mg for adolescents, with pharmacokinetic profiles comparable to adults. As of July 31, 2025, the objective response rate in NTRK fusion patients was 90%, with treatment-related adverse events primarily grade 1 or 2 and no dose-limiting toxicities observed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565180-en) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLbLxdHv:1","article_id":"2579066165","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579066165","pubTimestamp":1761796287,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InnoCare Pharma Ltd. has announced the latest results from a phase I/II clinical trial of zurletrectinib , a next-generation pan-TRK inhibitor, for pediatric and adolescent patients with advanced solid tumors. The data were presented as an oral presentation at the Congress of the International Society of Paediatric Oncology  2025. The study demonstrated favorable safety and promising antitumor activity in patients with NTRK/ROS1-altered solid tumors, including those resistant to first-generation TRK inhibitors. The recommended phase 2 dose was established at 7.2 mg/m for pediatric patients and 8 mg for adolescents, with pharmacokinetic profiles comparable to adults. As of July 31, 2025, the objective response rate in NTRK fusion patients was 90%, with treatment-related adverse events primarily grade 1 or 2 and no dose-limiting toxicities observed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK0239":"医药制造","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"诺诚健华医药报告Zurletrectinib在儿科实体瘤中取得有希望的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":0.9,"NDAQ":0.9},"content_text":"InnoCare Pharma Reports Promising Results for Zurletrectinib in Pediatric Solid Tumors\n    \n\n        InnoCare Pharma Ltd. has announced the latest results from a phase I/II clinical trial of zurletrectinib (ICP-723), a next-generation pan-TRK inhibitor, for pediatric and adolescent patients with advanced solid tumors. The data were presented as an oral presentation at the Congress of the International Society of Paediatric Oncology (SIOP) 2025. The study demonstrated favorable safety and promising antitumor activity in patients with NTRK/ROS1-altered solid tumors, including those resistant to first-generation TRK inhibitors. The recommended phase 2 dose was established at 7.2 mg/m² for pediatric patients and 8 mg for adolescents, with pharmacokinetic profiles comparable to adults. As of July 31, 2025, the objective response rate in NTRK fusion patients was 90%, with treatment-related adverse events primarily grade 1 or 2 and no dose-limiting toxicities observed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565180-en) on October 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579066165","isCrawlerRequest":true}